Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were crashing 46.6% lower as of 10:40 a.m. ET on Friday. The huge decline came after the drugmaker announced its first-quarter results before the ...

Iovance's Q1 revenue was sharply lower than expected. The company blamed the miss on lower production capacity due to annual maintenance at its cell therapy facility. However, Iovance's full-year ...

Iovance Biotherapeutics' stock has plummeted 90% since my 2020 "Buy" call, despite securing historic approval for its solid tumor cell therapy, Amtagvi because of delays, safety concerns, and high ...

Iovance Biotherapeutics shares fell 6.41% after appointing Dan Kirby as Chief Commercial Officer, signaling investor concerns. The decline reflects skepticism about the company's growth trajectory ...

One issue with Iovance's treatments is that they take a while to manufacture and administer -- 34 days in the case of Amtagvi ...

Newly commercial stage biopharma Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has delivered a couple of quarterly earnings beats since we last put in the spotlight in July of this year. The company ...

While that level of success is only obvious in hindsight, Iovance Biotherapeutics (NASDAQ: IOVA) is an emerging industry leader with significant potential. The company's tumor-infiltrating ...

Biotech stocks like Iovance Biotherapeutics (NASDAQ: IOVA) often look appealing because they could experience enormous growth in relatively short periods of time. Plus, over the long term ...

Iovance also announced the pricing of a secondary stock offering. The company could have more regulatory approvals on the way for its lead therapy in other countries. Because of the Presidents ...